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Introduction 
Hypersensitivity reactions to azathioprine are 
uncommon, and may be associated with fever, rash, 
myalgia, arthralgia, hypotension, interstitial nephri- 
tis, jaundice and pneumonitis (l-8). To our knowl- 
edge only one case of florid azathioprine-associated 
arthritis has been described in the medical literature 
(9). We report on a case of acute polyarthritis in a 
man taking azathioprine for interstitial lung disease, 
and describe the features of another eight cases 
reported to the World Health Organisation (WHO) 
Collaborating Centre for International Drug 
Monitoring. 
Case Report 
A 54-year-old male power-tool mechanic whose 
work regularly involved grinding of hard metals 
presented with a 2 yr history of progressive exer- 
tional dyspnoea, an unproductive cough, episodes 
of left pleuritic chest pain, and mild arthralgias of 
fingers, wrists and shoulders, without features of 
arthritis. He had a 37 pack-year cigarette-smoking 
history. Examination was unremarkable except for 
fine inspiratory crackles heard bilaterally in the lower 
zones. Chest radiographs showed small lung fields, 
no adenopathy, and increased interstitial markings 
with linear opacifications at the lung bases. Pul- 
monary function tests confirmed moderate restriction 
of lung volumes, and reduced transfer factor for 
carbon monoxide. The erythrocyte sedimentation 
rate (ESR) was 20 mmh ‘. The full blood count and 
differential count were normal, as was serum bio- 
chemistry. Anti-nuclear factor (ANF) was positive to 
a titre of l:lOO, rheumatoid factors were absent, and 
the serum angiotensin converting enzyme value was 
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39.6 units (40 & 10). A diagnosis of interstitial lung 
disease caused by hard metal exposure was made on 
the basis of history, increased proportions of eosino- 
phils (34%) and neutrophils (12%) in bronchoalveolar 
lavage, and open lung biopsy findings. These 
included interstitial fibrosis with extensive desquama- 
tion of alveolar lining cells and intra-alveolar 
macrophage accumulation, and the presence on 
transmission electron microscopy of multinucleate 
giant cells of both macrophage and type 2 
pneumocyte origin (10). 
He was treated with azathioprine 200 mg daily and 
prednisone 20 mg daily. Eight days later he devel- 
oped over 3-4 days severe myalgia and florid sym- 
metrical polyarthritis of the fingers, hands, elbows, 
shoulders, knees (with effusions), ankles and feet. 
There was no skin rash, fever, or lymphadenopathy. 
Mild muscle tenderness, but no weakness, was 
present. Respiratory examination was unchanged 
and further examination was normal. Urinalysis, full 
blood count and differential count were normal with- 
out eosinophilia. The ESR was 55 mmh- ‘. ANF was 
positive to a titre of 1:500. Repeated investigations 
for anti-DNA antibodies and rheumatoid factor were 
negative. Serum biochemistry, including serum urate 
and creatine kinase, was normal. Synovial fluid 
microscopy showed numerous polymorphonuclear 
leucocytes. Crystals were absent. Joint radiographs 
showed only soft tissue swelling. Azathioprine was 
withdrawn, prednisone continued, and non-steroidal 
anti-inflammatory drugs commenced. The arthritis 
and myalgia resolved completely over the following 
week. Re-challenge with azathioprine was not 
performed. 
Discussion 
Details of the eight cases recorded in the WHO 
Collaborating Centre for International Drug Moni- 
toring data base are given in Table 1. More common 
are arthralgia and myalgia with 33 cases of each 
(‘1 1995 W. B. Saunders Company Ltd 
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Table 1 Cases from WHO database of azdthioprine associated arthritis 
Case -4s Dose of Other Time to onset 
SIO. W Sex azathioprine drugs ADR(s) of symptoms Outcome 
1 51 F U Prednisolone Fever U Recovered 
Rash 
Arthritis 
2 48 M 100 mg daily - Fever U U 
Arthritis 
3 37 M U Clonidine Hepatitis U Recovered 
Bendrofluthiazide Pruritis 
Prednisone Arthritis 
4 61 F 100 mg daily Prednisone Conjunctivitis 24 days U 
Excedrin Arthritis 
5 48 M U Prednisolone Myalgia 10 days Recovered 
Arthritis 
6 40 F 50 mg daily - Arthritis U U 
I 51 F U Arthritis 10 days Recovered 
8 63 M 50 mg daily Prednisolone Fever 4 days Recovered 
Disopyramide Pneumonitis Recurrence 
Salbutamol Arthritis 
Beclometasone on rechallenge 
Acetylcysteine 
U, Unknown; ADR, adverse drug reaction. 
reported to the WHO. The mean age of patients on 
azathioprine in whom arthritis was reported was 51 
years, with an equal sex incidence. Arthritis was the 
only symptom reported in two cases, and in the other 
six cases was associated with such features as fever, 
rash, myalgias, hepatitis and pneumonitis. The time 
to onset of symptoms was 4-24 days and in the five 
cases where outcome was described, all patients 
recovered. Of note is that in the one patient who was 
rechallenged, there was recurrence of symptoms. In 
the one published report of severe polyarthritis and 
swinging fever in a patient taking azathioprine, 
recovery occurred on withdrawal, with recurrence of 
pyrexia of 39°C and severe polyarthritis within 1 h 
after re-challenge, involving the small joints of the 
hands and feet as well as the knees and elbows (8). 
Azathioprine-associated arthritis is rare, may be 
severe with involvement of small and large joints, and 
may occur alone or as part of a typical hypersensi- 
tivity syndrome. Recovery can be expected if the 
reaction is recognized and the drug withdrawn. 
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